WO1999018083A1 - N,n'-(sulfonyldi-1, 4-phenylene) bis (n'',n''- dimethylformamidin)-1, 2,3,4-tetrahydro- 6-methyl-2, 4-dioxo-5-pyrimidinsulfonate stimulant le metabolisme cellulaire et possedant une action immunotrope et antibacterienne, et procede de production - Google Patents
N,n'-(sulfonyldi-1, 4-phenylene) bis (n'',n''- dimethylformamidin)-1, 2,3,4-tetrahydro- 6-methyl-2, 4-dioxo-5-pyrimidinsulfonate stimulant le metabolisme cellulaire et possedant une action immunotrope et antibacterienne, et procede de production Download PDFInfo
- Publication number
- WO1999018083A1 WO1999018083A1 PCT/RU1998/000314 RU9800314W WO9918083A1 WO 1999018083 A1 WO1999018083 A1 WO 1999018083A1 RU 9800314 W RU9800314 W RU 9800314W WO 9918083 A1 WO9918083 A1 WO 9918083A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- compound
- methyl
- dioxo
- bis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/40—Y being a hydrogen or a carbon atom
Definitions
- the invention is related to organic chemistry, and more precisely to the new biologically active compound -methyl-2, 4-dioxo-5-pyrimidine sulfate stimulating cellular metabolism and possessing immune and anti-inflammatory activity, and.
- Chebny doses of these drugs should be reasonably high.
- the claimed invention is new and is not described in the literature.
- the main task of the invention was to create a new connection, easily dissolve in hot water and 0, 25% -0, 5% disruption, and increase the disruption
- This compound stimulates cellular metabolism (exchange of substances), which is an increase in the quantity of protein, protein. At the same time, it stimulates the stimulating action of the hydrated diuciphene, diuciphene, and other basic substances.
- This connection also shows the antimicrobial effect of the cure in treating leprosy mycobacterium, tuberculosis mycobacterium and hepatic mycobacterium.
- the claimed compound is an amorphous green and yellow in color, a melting point of 245-247 ° C. It is easy to use in hot water, we dissolve in dimethylphamide, dimethyl sulfide, and we do not dissolve in ordinary organic products. The structure is supported by the data of I and II of the spectroscopy.
- This compound is produced by heating the equimolecular amounts of diamine diphenylsulfone and 6-methyl-5-uracil-sulfulfide in dimethyl sulfamide.
- ⁇ e ⁇ i ⁇ usl ⁇ viya ⁇ not ⁇ b ⁇ a- zue ⁇ sya, ⁇ a ⁇ m ⁇ zhn ⁇ would byl ⁇ ⁇ zhida ⁇ , sul ⁇ namidn ⁇ e ⁇ iz- v ⁇ dn ⁇ e diamin ⁇ di ⁇ enilsul ⁇ na (DDS), and in ⁇ e ⁇ vuyu ⁇ che ⁇ ed ide ⁇ vzaim ⁇ deys ⁇ vie diamin ⁇ di ⁇ enilsul ⁇ na with dime ⁇ il ⁇ ma- mid ⁇ m ( ⁇ 5, 3.133.078; 30 S ⁇ ⁇ eyyz.1 :, b. ⁇ .Sagz ⁇ , Ca ⁇ . ⁇ _ ⁇ vic_ ⁇ grain, 1965, ⁇ .43, ⁇ 9, ⁇ .26
- the resulting dimethylphamidamide further develops salt from 6-methyl-acyl-5-sulfonic acid.
- the claimed compound was tested in an experiment on animals. The advantages of the claimed connection in comparison with the diusional illustration of table 1. - 4 -
- the number of compounds was divided into white, non-native mice weighing 18-20 g in a simple experience using the Litch-Field-Wilkson method (1).
- the influence of the claimed compound on the exchange of live animals has been studied.
- the study of the effect of the proposed product on the exchange of live car cells was compared with 6-methyl (methacyl), diuchenum and hydrated.
- test compound significantly increases the weight of the liver, liver, and the spleen.
- the test compound significantly increases the weight of the liver, liver, and the spleen.
- the claimed compound 7.7 0.7 61.9 ⁇ 0.7
- the first group is final: within 6 months, the mice of this group received through a probe 5 times a week 0.5 ml of extreme suspension.
- Experienced live groups were received during the test period of the studied drugs at a dose of 50 mg in 0 0.5 ml of a crusty suspension of 5 times a week. After 6 months, the animals were clogged up with a digital bias, they were banned from the study, and there were no accidents.
- bacteria were tested for 5 days, the infectious area was diluted in 2 ml of 0.1% albumin solution; from the 0.01 ml suspension, it was diluted, it was diluted, There are plenty of microbes on one mouse in each group. The results of the research are presented in Table 7.
- the claimed compound 20 0.014 ⁇ 0.007 50 0.001 ⁇ a ⁇ sledue ⁇ of ⁇ ivedenny ⁇ secy ⁇ , zayavlyaem ⁇ e s ⁇ edine- of ⁇ bladae ⁇ vys ⁇ y ba ⁇ e ⁇ i ⁇ s ⁇ a ⁇ iches ⁇ y a ⁇ ivn ⁇ s ⁇ yu ⁇ n ⁇ - si ⁇ eln ⁇ mi ⁇ ba ⁇ e ⁇ y le ⁇ y, ⁇ ev ⁇ s ⁇ dyaschey an ⁇ imi ⁇ ba ⁇ e- ⁇ ialnuyu a ⁇ ivn ⁇ s ⁇ ⁇ a ⁇ diutsi ⁇ na, and ⁇ a ⁇ gid ⁇ a ⁇ a diutsi ⁇ na. Otherwise, it should be noted that 50% of the animals in the group, who received the treatment with the claimed compound, did not experience any disease that caused them to be ill.
- the beneficial activity of the claimed compounds in comparison with methacyl, diuchene and hydrated diuciphone was studied on the microbial strain "Casseteta".
- the basic therapy of tuberculosis was cultivated in a liquid environment of the School of Culture (6) with 10% human plasma. ⁇ schreib Each product containing 2 ml of medium with the studied substances in a different concentration was inoculated with 0, 2 ml of suspension of bacteriosis, and 10% of the disease was Incubated for 10 days ⁇ and 37 ° ⁇ .
- the minimum inhibitory endoscopy was attributed to the absence of a small amount of tuberculosis disease in the case with the smallest content of the studied substance.
- Crops are maintained at 34 ° C for 10 days, then 5 5 minutes are cultivated at 1,500 and 1,500.
- the horticultural fluid is drained through the edge: the sediment is deposited on the glass, it is equally spread, fixed, and absorbed (8).
- Table 9 means: + - availability of the unit. 5 - - lack of space. - single microbial therapy in a few field of vision. The investigated compounds are less than those of the comparison, and in most cases it is investigated with 0 percent concentration and the bactericidal effect is found in the solution. 1 and £ u.
- the claimed compound increases the cost of administration (depending on the method of administration) by 3.8 and 4.8 times, which results in a 2-fold decrease in efficiency.
- phased activity of the claimed compounds increases by more than 1.5 times, and when the amount of hydration is increased, it is 12–17% more active. Perhaps this is due to the practical complete inappropriateness of the water.
- the Stimulation Index calculates the increase in the number of blasts in the experienced group to the number of blunders in the online group. In general, all the studied drugs stimulate the lymphocytes (the formation of the blinks), but the highest connection rate is the connection to the connection (23), which is 20 (); at diucion.
- a flask containing 24.8 g (0.1 mol) of 4, 4-diamine di-phenyl sulfone in 300 ml of dry dimethylamide and stirring and temperature of 25-30 ° C is 0.25 (0.2) 47.3 ° C. 6-methyl-acyl-5-sulfonic acid. Stir for 1 hour at a temperature of 50-53 ° C, cool and filter the remaining plant. The raw product is stirred for 2 hours at a temperature of 200 ml. The yellow powder boils 1 hour in 250 ml
- the claimed compound is ⁇ , ⁇ '- (sulfulfyldi-1, 4-phenylene) bis ( ⁇ ", ⁇ " -dimethylphammamidine) -1,2, 3, 4-tetrahydro-6-methyl-2, 4-dioxo-5-pyrimidine , s ⁇ imuli ⁇ ue ⁇ ⁇ le ⁇ chny Me- 25 ⁇ ab ⁇ lizm and ⁇ bladae ⁇ immun ⁇ n ⁇ y and an ⁇ imi ⁇ ba ⁇ e ⁇ ialn ⁇ y a ⁇ ivn ⁇ s ⁇ yu and na ⁇ di ⁇ ⁇ imenenie in medicine for the treatment of ⁇ aches ⁇ ve s ⁇ eds ⁇ va le ⁇ y, ⁇ ube ⁇ uleza and d ⁇ ugi ⁇ immun ⁇ de- ⁇ itsi ⁇ ny ⁇ zab ⁇ levany, chas ⁇ ⁇ sl ⁇ zhenny ⁇ mi ⁇ ba ⁇ e ⁇ ialnymi in ⁇ e ⁇ tsiyami.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU14476/99A AU1447699A (en) | 1997-10-07 | 1998-10-05 | N,n'-(sulphonyldi-1, 4-phenylen) bis (n'',n''- dimethylformamidin)-1, 2,3,4-tetrahydro- 6-methyl-2, 4-dioxo-5-pyrimidinsulphonate for stimulating cellular metabolism and having an immunotropic and anti-bacterial activity and method for producing the same |
UA2000052577A UA46163C2 (uk) | 1997-10-07 | 1998-10-05 | N, n'-(сульфонілди-1,4-фенілен)біс(n",n"-диметилформамідин)-1,2,3,4-тетрагідро-6-метил-2,4-діоксо-5-піримідинсульфонат, що стимулює клітинний метаболізм і має імунотропну та антимікобактеріальну активність, і спосіб його отримання |
EA200000370A EA002153B1 (ru) | 1997-10-07 | 1998-10-05 | N,n'-(сульфонилди-1,4-фенилен)бис(n'',n''-диметилформамидин)-1,2,3,4-тетрагидро-6-метил-2,4-диоксо-5-пиримидинсульфонат, стимулирующий клеточный метаболизм и обладающий иммунотропной и антимикобактериальной активностью, и способ его получения |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU97117514 | 1997-10-07 | ||
RU97117514A RU2136668C1 (ru) | 1997-10-07 | 1997-10-07 | N,n'-(сульфонилди-1,4-фенилен)бис(n'',n''- диметилформамидин)1,2,3,4-тетрагидро-6-метил-2,4- диоксо-5-пиримидинсульфонат, стимулирующий клеточный метаболизм и обладающий иммунотропной и антимикобактериальной активностью |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999018083A1 true WO1999018083A1 (fr) | 1999-04-15 |
Family
ID=20198302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU1998/000314 WO1999018083A1 (fr) | 1997-10-07 | 1998-10-05 | N,n'-(sulfonyldi-1, 4-phenylene) bis (n'',n''- dimethylformamidin)-1, 2,3,4-tetrahydro- 6-methyl-2, 4-dioxo-5-pyrimidinsulfonate stimulant le metabolisme cellulaire et possedant une action immunotrope et antibacterienne, et procede de production |
Country Status (5)
Country | Link |
---|---|
AU (1) | AU1447699A (fr) |
EA (1) | EA002153B1 (fr) |
RU (1) | RU2136668C1 (fr) |
UA (1) | UA46163C2 (fr) |
WO (1) | WO1999018083A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001032650A2 (fr) * | 1999-11-05 | 2001-05-10 | Alexandr Leonidovich Reshetov | Sels alcalins de n-(6-alkyle-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinesulfone)-n'-isonicotinoylhydrazide pouvant presenter une activite antimicrobienne et immunotrope, methode de preparation de ces sels, utilisation de ces sels comme immunomodulateurs et composition pharmaceutique a base de ces sels |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005092344A1 (fr) * | 2004-03-26 | 2005-10-06 | Zakrytoe Aktsionernoe Obschestvo 'novaya Linia' | Preparation medicinale |
RU2550948C1 (ru) * | 2014-06-20 | 2015-05-20 | Общество с ограниченной ответственностью "Научно-внедренческий центр "Агроветзащита" | N,n'-(сульфонилди-п-фенилен)бис-n'',n''-диметилформамидин, обладающий акарицидным действием |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1511517A (en) * | 1974-09-18 | 1978-05-17 | Sirius | Alpha-(diethylamino)-propiophenone orotate a process for its preparation and its use in pharmaceutical compositions |
SU687074A1 (ru) * | 1978-01-06 | 1979-09-25 | 2-Московский Ордена Ленина Государственный Медицинский Институт Им. Н.И.Пирогова | 4-Амино-4 -дифенилсульфонаммониева соль 6-метил-2,4-диоксо-1,2,3,4тетрагидропиримидина, обладающа противолепрозной и противосудорожной активностью |
RU2044728C1 (ru) * | 1990-08-21 | 1995-09-27 | Научно-исследовательская лаборатория иммунохимиотерапии лепры с опытно-экспериментальным производством иммуномодуляторов и клиниками ИДС | Оротат гидразида изоникотиновой кислоты, обладающий антимикобактериальной и иммунотропной активностью |
-
1997
- 1997-10-07 RU RU97117514A patent/RU2136668C1/ru not_active IP Right Cessation
-
1998
- 1998-10-05 AU AU14476/99A patent/AU1447699A/en not_active Abandoned
- 1998-10-05 UA UA2000052577A patent/UA46163C2/uk unknown
- 1998-10-05 WO PCT/RU1998/000314 patent/WO1999018083A1/fr active Application Filing
- 1998-10-05 EA EA200000370A patent/EA002153B1/ru not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1511517A (en) * | 1974-09-18 | 1978-05-17 | Sirius | Alpha-(diethylamino)-propiophenone orotate a process for its preparation and its use in pharmaceutical compositions |
SU687074A1 (ru) * | 1978-01-06 | 1979-09-25 | 2-Московский Ордена Ленина Государственный Медицинский Институт Им. Н.И.Пирогова | 4-Амино-4 -дифенилсульфонаммониева соль 6-метил-2,4-диоксо-1,2,3,4тетрагидропиримидина, обладающа противолепрозной и противосудорожной активностью |
RU2044728C1 (ru) * | 1990-08-21 | 1995-09-27 | Научно-исследовательская лаборатория иммунохимиотерапии лепры с опытно-экспериментальным производством иммуномодуляторов и клиниками ИДС | Оротат гидразида изоникотиновой кислоты, обладающий антимикобактериальной и иммунотропной активностью |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001032650A2 (fr) * | 1999-11-05 | 2001-05-10 | Alexandr Leonidovich Reshetov | Sels alcalins de n-(6-alkyle-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinesulfone)-n'-isonicotinoylhydrazide pouvant presenter une activite antimicrobienne et immunotrope, methode de preparation de ces sels, utilisation de ces sels comme immunomodulateurs et composition pharmaceutique a base de ces sels |
WO2001032650A3 (fr) * | 1999-11-05 | 2002-05-10 | Alexandr Leonidovich Reshetov | Sels alcalins de n-(6-alkyle-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinesulfone)-n'-isonicotinoylhydrazide pouvant presenter une activite antimicrobienne et immunotrope, methode de preparation de ces sels, utilisation de ces sels comme immunomodulateurs et composition pharmaceutique a base de ces sels |
Also Published As
Publication number | Publication date |
---|---|
EA200000370A1 (ru) | 2000-10-30 |
RU2136668C1 (ru) | 1999-09-10 |
UA46163C2 (uk) | 2002-05-15 |
AU1447699A (en) | 1999-04-27 |
EA002153B1 (ru) | 2001-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ziv et al. | The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves | |
WO1995022336A1 (fr) | Agent immunomodulateur et reducteur du dysfonctionnement du systeme de regulation de la propagation de cellules tissulaires | |
CN102935222A (zh) | 三价铁卟啉短肽化合物在抗2型糖尿病药物制备中的用途 | |
WO1999018083A1 (fr) | N,n'-(sulfonyldi-1, 4-phenylene) bis (n'',n''- dimethylformamidin)-1, 2,3,4-tetrahydro- 6-methyl-2, 4-dioxo-5-pyrimidinsulfonate stimulant le metabolisme cellulaire et possedant une action immunotrope et antibacterienne, et procede de production | |
CN101322746B (zh) | 二次发酵法天然药物制剂、制备方法及用途 | |
Gibson et al. | Development of resistance to dihydrostreptomycin by Bacterium coli | |
WO2005068491A1 (fr) | Peptides antitumoraux et antiviraux | |
WO1999007699A1 (fr) | Modulateur immunologique ayant une activite antimicrobienne et anti-mycobacterienne, procede de production de ce modulateur et preparation pharmaceutique permettant de traiter les mycobacterioses ainsi que les affections chroniques et non specifiques des poumons, les maladies sexuellement transmissibles et le deficit immuni | |
JPH1087500A (ja) | ポリ(ヘキサメチレン)ビグアニドまたはその塩を有効成分とする腫瘍治療剤 | |
EP0348507A4 (en) | Pharmaceutical preparation for individual prophylaxis of venereal diseases and curing urogenital trichomoniasis | |
CN101095743A (zh) | 治疗妇科疾病的外用药物组合物及其制备方法和用途 | |
CN112791037A (zh) | 一种组合活性物及其制备方法和其在制备舒缓皮肤过敏的产品或药物中的应用 | |
WO1998043982A1 (fr) | Derives tetracycliques de la pyrimidine | |
RU2500411C2 (ru) | Способ индивидуального подбора препаратов, содержащих пробиотические штаммы лактобактерий для эффективной интравагинальной терапии | |
US20030152551A1 (en) | 2-Methyl-3-butenyl-1-pyrophosphoric acid salt and agent for treating lymphocytes | |
JPS5839624A (ja) | 抗腫瘍剤 | |
CN111329790B (zh) | 一种女士抑菌低泡洗液及其制备方法 | |
Schütz | The effect of barbiturates on the cholinesterase in different tissues | |
RU2438691C1 (ru) | Средство, обладающее гемостимулирующим, антимутагенным, противоопухолевым, церебропротекторным, антигипоксическим, ноотропным, анксиолитическим и противоневротическим действием | |
Jungi et al. | GENETIC CONTROL OF CELL‐MEDIATED IMMUNITY IN THE RAT: II. SHARING OF EITHER THE RTI. A OR RTI. B LOCUS IS SUFFICIENT FOR TRANSFER OF ANTIMICROBIAL RESISTANCE | |
POLOVA | SELECTION OF FILTERING MATERIAL IN THE DEVELOPMENT OF A SPRAY BASED ON SILVER AND COPPER CITRATES | |
Сазонов | Age features of morphogenetic properties of lymphoid cells of the spleen | |
Whitehead et al. | TOXICITY STUDY ON VICCILLIN S (AN AMPICILLIN-CLOXACILLIN COMBINATION) Subacute Toxicity of Viccillin S in Female Beagle Dogs | |
Jordan | The Science Committee Of The British Medical Association. Report On Urinary Antiseptics | |
DE1184757B (de) | Verfahren zur herstellung von reaktionsprodukten aus 3,4-dimethylphenol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO SD SE SG SI SK TJ TM TR TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200000370 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |